Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans

Acta Physiologica Scandinavica

Volumn 160, Issue 4, 1997, Pages 413-422

  Larsson, H ^a   Holst, J J ^b   Ahrén, Bo ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

GLP 1; Glucose metabolic clearance rate; Rate of glucose appearance; Rate of glucose disappearance; Somatostatin

Indexed keywords

GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; SOMATOSTATIN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GLUCAGON RELEASE; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; HUMAN; HUMAN EXPERIMENT; INSULIN RELEASE; INTRAVENOUS DRUG ADMINISTRATION; LIVER; METABOLIC CLEARANCE RATE; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0030798846     PISSN: 00016772     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-201X.1997.00161.x     Document Type: Article

References (35)

1. Blackmore, P., Mojsov, S., Exton, J.H. & Habener, J.F. 1991. Absence of insulinotropic glucagon-like peptide-I (7-37) receptors on isolated rat liver hepatocytes. FEBS Lett 283, 7-10.
2. Campos, R.V., Lee, Y.C. & Drucker, D.J. 1994. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology 134, 2156-2164.
3. Cherrington, A.D., Stevenson, R.V. & Steiner, K.E. 1987. Glucagon as a regulator of hepatic glucose production in vivo. Biochem Soc Trans 15, 1023-1027.
4. D'Alessio, D.A., Kahn, S.E., Luesner, C.R. & Ensinck, J.W. 1994. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93, 2263-2266.
5. 14 glucose. Recent Prog Hurm Res 19, 445-488.
6. Egan, J.M., Montrose-Rafizadeh, C., Wang, Y., Bernier, M. & Roth, J. 1994. Glucagon-like peptide-1 (7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action, Endocrinology 135, 2070-2075.
7. Fehmann, H.C., Göke, R. & Göke, B. 1995. Cell and molecular biology of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulin releasing polypeptide. Endocr Rev 16, 390-410.
8. (7-36) amide: influences on basal and stimulated insulin and glucagon secretion in the mouse. Pancreas 6, 208-215.
9. Gutniak, M.K., Larsson, M.K., Heiber, S.J., Juneskans, O.T., Holst, J.J. & Ahrén, B. 1996. Potential therapeutic levels of glucagon-like peptide-1 achieved in humans by a buccal tablet. Diabetes Care 19, 843-848.
10. Gutniak, M., Orskov, C., Hoist, J.J., Ahrén, B. & Efendic, S. 1992. Antidiabetogenic effect of glucagon-like peptide-1 (7-36 amide) in normal subjects and patients with diabetes mellitus. N Engl J Med 326, 1316-1322.
11. Holst, J.J., Orskov, C., Schwartz, T.W. & Nielsen, O.V. 1987. Truncated glucagon-like peptide 1, an insulin-releasing hormone from the distal gut. FEBS Lett 211, 169-174.
12. Hvidberg, A., Toft Nielsen, M., Hilsted, J., Orskov, C. & Holst, J.J. 1994. Effect of glucagon-like peptide-1 (proglucagon 78-107 amide) on hepatic glucose production in healthy man. Metabolism 43, 104-108.
13. Jia, C., Brown, J.C., Ma, P., Pederson, R.A. & McIntosh, C.H.S. 1995. Effects of glucose-dependent insulinotropic polypeptide and glucagon-like-peptide-l-(7-36) on insulin secretion. Am J Physiol 268, E645-E651.
14. Kreymann, B., Williams, G., Ghatei, M.A. & Bloom, S.R. 1987. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2, 1300-1303.
15. Mojsov, S., Heinrich, G., Wilson, I.B., Ravazzola, M., Orci, L. & Habener, J.F. 1986. Proglucagon gene expression in pancreas and intestine diversifies at the level of posttranslational processing. J Biol Chem 261, 11880-11889.
16. Nauck, M.A., Heimesaat, M.M., Orskov, C., Holst, J.J., Ebert, R. & Creutzfeldt, W. (1993a) Preserved incretin activity of glucagon-like peptide-1 (7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Intest 91, 301-307.
17. Nauck, M.A., Kleine, N., Orskov, C., Holst, J.J., Willms, B. & Creutzfeldt, W. (1993b) Normalization of fasting hyperglycemia by exogeneous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36, 741-744.
18. Norusis, M.J. 1992. SPSS for Windows. Base system users guide, Release 5.0. Chicago, SPSS Inc.
19. Orskov, C. 1992. Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 35, 701-711.
20. Oskov, L., Holst, J.J., Moller, J., Orskov, C., Moller, N., Alberti, K.G.M.M. & Schimitz, O. 1996. GLP-1 does not acutely affect insulin sensitivity in healthyman. Diabetologia 39, 1227-1232.
21. Orskov, C. & Poulsen, S.S. 1991. Glucagon-like peptide-1-(7-36)-amide receptors only in islets of Langerhans. Autoradiographic survey of extracerebral tissues in rats. Diabetes 40, 1292-1296.
22. Orskov, C., Rabenhöj, L., Kofod, H., Wettergren, A. & Holst, J.J. 1994. Production and secretion of amidated and glycine-extended glucagon-like peptide-1 (GLP-1) in man. Diabetes 43, 535-539.
23. Oskov, L., Holst, J.J., Moller, J., Orskov, C., Moller, N., Alberti, K.G.M.M. & Schmitz, O. 1996. GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia 39, 1227-1232.
24. Qualmann, C., Nauck, M.A., Holst, J.J., Orskov, C. & Creutzfeldt, W. 1995. Insulinotropic actions ot intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the tasting state in healthy subjects. Acta Diabetol 32, 13-16.
25. Rachman, J. & Turner, R.C. 1995. Drugs on the horizon for treatment of type 2 diabetes. Diabetic Med 12, 467-478.
26. Ritzel, R., Orskov, C., Holst, J.J. & Nauck, M.A. 1995. Pharmacokinetic, insulinotropic and glucagonostatic properties of GLP-1 (7-36 amide) after subcutaneous injection in healthy volunteers. Dose-response relationships. Diabetologia 38, 720-725.
27. Steele, R. 1959. Influences of glucose loading and of injected insulin on hepatic glucose output. Ann NY Acad Sci 82, 420-430.
28. Steiner, K.E., Williams, P.M., Lacy, W.W. & Cherrington, A.D. 1990. Effects of insulin on glucagon-stimulated glucose production in the conscious dog. Metabolism 39, 1325-1333.
29. Toft-Kielsen, M., Madsbad, S. & Holst, J.J. 1996. The effect of glucagon-like peptide 1 (GLP-1) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 45, 552-556.
30. Valverde, I., Morales, M., Clemente, F., López-Delgado, M.I., Delgado, E., Perea, A. & Villanueva-Peǹacarrillo, M.L. 1994. Glucagon-like peptide 1: a potent glycogenic hormone. FEBS Lett 349, 313-316.
31. Van Dijk, G., Lindskog, S., Holst, J.J., Steffens, A.B. & Ahrén, B. 1996. Effects of glucagon-like peptide 1 on glucose turnover in rats. Am J Physiol 270, E1015-E1021.
32. Villanueva-Penacarrillo, M.L., Delgado, M., Trapote, M.A., Alcantara, A., Clemente, F., Luque, M.A., Perea, A. & Valverde, I. 1995. Clucagon-like peptide-1 binding to rat hepatic membranes. J Endocrinol 146, 183-189.
33. Wettergren, A., Schjoldager, B., Mortensen, P.M., Myhre, J., Christiansen, J. & Holst, J.J. 1993. Truncated GLP-1 (proglucagon 78- 107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38, 665-673.
34. Willms, B., Werner, J., Holst, J.J., Orskov, C., Creutzfeldt, W. & Nauck, M.A. 1996. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogeneous glucagon-like peptide-1 (GLP-l)-(7-36) amide in type 2 (noninsulin dependent) diabetic patients. J Clin Endocrinol Metab 81, 327-332.
35. World Health Organization. 1985. Diabetes Mellitus: Report of a study group. Geneva, World Health Organization, Technical Report Series no. 727.